Back to search

Peptide record

TPDB06309

Antibacterial Anticancer Toxicity standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06309
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0
standard
No
A 11-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and CancerPPD 2.0, with an available 3D structural model.
Sequence
FLGWLFKVASK
Physicochemical Analysis
C66H98N14O13
RNDCEQHIMPTY
LKF
1295.59
10.60
2
0
7
+2
-3.21
0.845
106.36
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
424.52
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
2
L
2
K
0
M
2
F
0
P
1
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 2 K: 2 M: 0 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
11
C66H98N14O13
1295.59
10.60
+2
-3.21
0.845
Evidence Records 3 records
Evidence 1 Activity

Activity

12% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
12% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic peptide engineering and structural characterization to search for the shortest antimicrobial peptide analogue of gaegurin 5. | J Biol Chem | 2004
Evidence 2 Activity

Activity

IC50
Toxicity
311.38 µg/mL
Cytotoxic
IC50 | 311.38 | µg/mL | target cell: Normal breast cells MCF-10a

Target

Normal breast cells MCF-10a

Source & Reference

NA
DBAASP
Structural determinants for the membrane interaction of novel bioactive undecapeptides derived from gaegurin 5. | J Med Chem | 2006
Evidence 3 Activity

Activity

IC50
Toxicity
311.38 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 12% Hemolysis=100 µg/ml | Cytotoxicity: MCF-10a: IC50=311.38 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2006 Aug 10 49(16):4886-95.